Danaher Corporation vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $102.41 (market cap $28.50B). The key difference: Danaher Corporation is far larger — about 5.4× iShares iBoxx $ Inv Grade Corporate Bond ETF's market cap, and Danaher Corporation pays a 0.74% dividend while iShares iBoxx $ Inv Grade Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and iShares iBoxx $ Inv Grade Corporate Bond ETF for 125 Days on average.
| DHR | LQD | |
|---|---|---|
Market Cap | $152.87B | $28.50B |
Volume | 5,228,698 | 37,320,110 |
Sector | Health | Fixed Income |
52-Week High | $242.05 | $112.91 |
52-Week Low | $161.91 | $101.83 |
Typical Hold Time | 69 Days | 125 Days |
Enterprise Value | $175.08B | — |
Dividend Yield | 0.74% | — |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, down 0.47% on the day, with a bullish technical signal from moving averages and support at $214. The company shows strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news includes a declared $0.40 dividend payable in October 2026 and significant institutional buying, such as Bank of America's new $993.8 million stake in Q2 2026.
The outlook is positive with a consensus price target of $230.31, implying 5.9% upside, supported by 70% analyst buy ratings. Risks include elevated valuation multiples like a P/E of 38.76 and fluctuating cash flows, but earnings growth in biotechnology and steady revenue provide a solid foundation for investor confidence.
LQD trades at $102.47 with a slight 0.34% daily gain amid a challenging bond market environment. The ETF shows bearish technical signals with moving averages indicating downward pressure, though oscillators remain neutral. Recent news highlights significant short interest growth of 53.1% in September 2026 and concerns about rising Treasury yields impacting investment-grade corporate bonds.
The outlook remains cautious as rising interest rates pressure bond ETFs, though LQD's 4.8% yield and high-quality portfolio provide some stability. Key risks include further bond market volatility and economic uncertainty, while institutional activity shows mixed sentiment with elevated short positions.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →